NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Core Viewpoint - Neumora Therapeutics, Inc. is facing a securities class action lawsuit related to its September 2023 IPO, with a lead plaintiff deadline set for April 7, 2025 [1][3]. Group 1: Class Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6]. - The lawsuit alleges that the Offering Documents contained false or misleading statements regarding the Phase Two Trials and their implications for the Phase Three Program [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. - Investors are advised that until a class is certified, they are not represented unless they retain counsel [7].